IDenta Corp. (IDTA)
USD 0.45
(0.0%)
USD 0.45
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.01 Million USD | -7.83% |
| 2022 | 1.09 Million USD | 37.53% |
| 2021 | 799.31 Thousand USD | 10.98% |
| 2020 | 720.26 Thousand USD | 3.66% |
| 2019 | 694.81 Thousand USD | 17.41% |
| 2018 | 591.75 Thousand USD | -3.2% |
| 2017 | 611.3 Thousand USD | 9.28% |
| 2016 | 559.37 Thousand USD | -40.43% |
| 2015 | 939.05 Thousand USD | 18.09% |
| 2014 | 795.2 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 933.35 Thousand USD | -3.99% |
| 2024 Q1 | 972.12 Thousand USD | -4.05% |
| 2023 Q4 | 1.01 Million USD | 8.19% |
| 2023 Q1 | 1.05 Million USD | -4.39% |
| 2023 Q2 | 996.9 Thousand USD | -5.15% |
| 2023 FY | 1.01 Million USD | -7.83% |
| 2023 Q3 | 936.44 Thousand USD | -6.06% |
| 2022 Q3 | 757.58 Thousand USD | -6.57% |
| 2022 FY | 1.09 Million USD | 37.53% |
| 2022 Q1 | 775.86 Thousand USD | -2.93% |
| 2022 Q2 | 810.86 Thousand USD | 4.51% |
| 2022 Q4 | 1.09 Million USD | 45.1% |
| 2021 Q1 | 758.83 Thousand USD | 5.36% |
| 2021 FY | 799.31 Thousand USD | 10.98% |
| 2021 Q4 | 799.31 Thousand USD | -5.43% |
| 2021 Q3 | 845.17 Thousand USD | 16.33% |
| 2021 Q2 | 726.55 Thousand USD | -4.25% |
| 2020 Q2 | 981.67 Thousand USD | 46.43% |
| 2020 Q1 | 670.38 Thousand USD | -3.52% |
| 2020 Q3 | 622.46 Thousand USD | -36.59% |
| 2020 FY | 720.26 Thousand USD | 3.66% |
| 2020 Q4 | 720.26 Thousand USD | 15.71% |
| 2019 Q4 | 694.81 Thousand USD | 2.35% |
| 2019 Q1 | 581.27 Thousand USD | -1.77% |
| 2019 Q2 | 715.69 Thousand USD | 23.12% |
| 2019 FY | 694.81 Thousand USD | 17.41% |
| 2019 Q3 | 678.86 Thousand USD | -5.15% |
| 2018 Q2 | 660.39 Thousand USD | 0.67% |
| 2018 FY | 591.75 Thousand USD | -3.2% |
| 2018 Q4 | 591.75 Thousand USD | -5.89% |
| 2018 Q3 | 628.81 Thousand USD | -4.78% |
| 2018 Q1 | 656 Thousand USD | 15.32% |
| 2017 FY | 611.3 Thousand USD | 9.28% |
| 2017 Q4 | 568.83 Thousand USD | 0.0% |
| 2016 FY | 559.37 Thousand USD | -40.43% |
| 2015 FY | 939.05 Thousand USD | 18.09% |
| 2014 FY | 795.2 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | 71.919% |
| Arrayit Corporation | 7.49 Million USD | 86.485% |
| Atlantic International Corp. | 3.82 Million USD | 73.537% |
| Biocept, Inc. | 22.01 Million USD | 95.397% |
| Bioqual, Inc. | 18.93 Million USD | 94.65% |
| CardioGenics Holdings Inc | 1.79 Million USD | 43.554% |
| DermTech, Inc. | 64.75 Million USD | 98.435% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 99.862% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 91.82% |
| iMD Companies, Inc. | 1.67 Million USD | 39.485% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 96.402% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -240.046% |
| InVitro International | 78.99 Thousand USD | -1182.641% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 94.865% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -683.59% |
| Medical Imaging Corp. | 9.51 Million USD | 89.354% |
| NovelStem International Corp. | 4.2 Million USD | 75.912% |
| Optigenex Inc. | 9.57 Million USD | 89.414% |
| PharmChem, Inc. | 558.64 Thousand USD | -81.359% |
| Proteome Sciences plc | 18.48 Million USD | 94.52% |
| Response Genetics, Inc | 15.86 Million USD | 93.615% |
| Rennova Health, Inc. | 49.66 Million USD | 97.96% |
| RushNet, Inc. | 6.23 Million USD | 83.761% |
| ScreenPro Security Inc. | 1.6 Million USD | 36.701% |
| Stella Diagnostics Inc. | 18 Million USD | 94.373% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | 87.65% |
| Todos Medical Ltd. | 50.15 Million USD | 97.98% |